4th Quarter - Termination

HELIX, INC. for HELIX, INC.

Firm
Client
Income
—
Expenses
$10,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Dec 31, 2024

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: Veterans Affairs, Dept of (VA); SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH)

Medical/Disease Research/Clinical Labs MED

Oversight of Lab Developed Tests, express legislative authority. Expanded access to VAMC genetic and pharmacogemomic testing

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Veterans Affairs, Dept of (VA)

Science/Technology SCI

Whole Exome Sequencing, DNA screening testing and diagnostics, access to clinical trials

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: Natl Institutes of Health (NIH); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; SENATE

Veterans VET

Veteran access to genetic testing, updating electronic health records for VAMCs.

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.